Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640909 | 0.98 | HTT (0.60) | HTTDRD2MEN1KMT2AALDH1A1 | |
| SCHEMBL13641206 | 0.86 | MEN1 (0.53) | HTTDRD2MEN1KMT2AALDH1A1 | |
| SCHEMBL13640911 | 0.86 | TSHR (0.69) | HTTMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL13641090 | 0.85 | MEN1 (0.70) | HTTMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL13641087 | 0.85 | MEN1 (0.70) | HTTMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL16406276 | 0.84 | ALDH1A1 (0.68) | HTTDRD2MEN1KMT2AALDH1A1 | |
| SCHEMBL13641151 | 0.83 | MEN1 (0.46) | HTTDRD2MEN1KMT2AALDH1A1 | |
| SCHEMBL13641117 | 0.82 | HTT (0.71) | HTTDRD2MEN1KMT2AALDH1A1 | |
| SCHEMBL13641058 | 0.82 | HTT (0.67) | HTTDRD2MEN1KMT2AALDH1A1 | |
| SCHEMBL10237222 | 0.81 | HTT (0.82) | HTTDRD2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDRENS MEDICAL CENTER (US) | 2026-04-30 | — | — | US | disclosed |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340554-B2 | IRAK inhibitors and uses thereof | NIMBUS IRIS, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-01-22 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025093-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTT 3378/4885DRD2 4755/4885MEN1 3741/4885 |
| US-20160296524-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTT 3378/4885DRD2 4755/4885MEN1 3741/4885 |
| US-12171755-B2 | PAPD5 inhibitors and methods of use thereof | PARP15, PAPSS1, PGA5 | HTT 3373/4885DRD2 4183/4885MEN1 3710/4885 |
| US-20260115182-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, TERT, BRCA1 | HTT 363/4885DRD2 2152/4885MEN1 2876/4885 |
| US-20210177827-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | PARP15, PAPSS1, PGA5 | HTT 3373/4885DRD2 4183/4885MEN1 3710/4885 |
| US-20120283238-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTT 3378/4885DRD2 4755/4885MEN1 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.